Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Kinetin Riboside, also known as N6-furfuryladenine riboside, is a naturally occurring nucleoside found in plants and some microorganisms. It is a white solid with unique chemical properties that make it a promising compound for various applications in the pharmaceutical and biotechnology industries.

4338-47-0 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 4338-47-0 Structure
  • Basic information

    1. Product Name: KINETIN RIBOSIDE
    2. Synonyms: n-furfuryl-adenosin;6-FURFURYLAMINOPURINE RIBOSIDE;Kinetin-9-riboside;KINETIN RIBOSIDE;FURFURYLAMINOPURINE RIBOSIDE, 6-;N-(2-furanylmethyl)-1H-purin-6-amine riboside;KINETIN RIBOSIDE PLANT CELL CULTURE*TEST ED;6-Furfurylaminopurine Riboside, N6-Furfuryladenosine
    3. CAS NO:4338-47-0
    4. Molecular Formula: C15H17N5O5
    5. Molecular Weight: 347.33
    6. EINECS: 224-389-3
    7. Product Categories: Nucleotides and Nucleosides;Bases & Related Reagents;Nucleotides
    8. Mol File: 4338-47-0.mol
  • Chemical Properties

    1. Melting Point: 152-154 °C
    2. Boiling Point: 683.7 °C at760mmHg
    3. Flash Point: 367.3 °C
    4. Appearance: white solid
    5. Density: 1.78 g/cm3
    6. Vapor Pressure: 1.25E-19mmHg at 25°C
    7. Refractive Index: 1.798
    8. Storage Temp.: 2-8°C
    9. Solubility: DMSO (Slightly), Ethanol (Slightly, Heated, Sonicated), Methanol (Very Slightly,
    10. PKA: 13.11±0.70(Predicted)
    11. Stability: Hygroscopic
    12. CAS DataBase Reference: KINETIN RIBOSIDE(CAS DataBase Reference)
    13. NIST Chemistry Reference: KINETIN RIBOSIDE(4338-47-0)
    14. EPA Substance Registry System: KINETIN RIBOSIDE(4338-47-0)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: 24/25
    4. WGK Germany: 3
    5. RTECS: AU7400200
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 4338-47-0(Hazardous Substances Data)

4338-47-0 Usage

Uses

Used in Pharmaceutical Industry:
Kinetin Riboside is used as an anticancer agent for its potential to inhibit the growth and proliferation of cancer cells. It is also utilized as an antiviral agent, demonstrating effectiveness against a range of viral infections by interfering with the viral replication process.
Used in Biotechnology Industry:
In addition to its pharmaceutical applications, Kinetin Riboside is also used in the biotechnology industry for its role in cell growth and development. It can be employed in research and development of new therapies and treatments for various diseases, as well as in the study of cellular processes and mechanisms.

Check Digit Verification of cas no

The CAS Registry Mumber 4338-47-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,3,3 and 8 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 4338-47:
(6*4)+(5*3)+(4*3)+(3*8)+(2*4)+(1*7)=90
90 % 10 = 0
So 4338-47-0 is a valid CAS Registry Number.
InChI:InChI=1/C15H17N5O5/c21-5-9-11(22)12(23)15(25-9)20-7-19-10-13(17-6-18-14(10)20)16-4-8-2-1-3-24-8/h1-3,6-7,9,11-12,15,21-23H,4-5H2,(H,16,17,18)/t9-,11-,12-,15-/m1/s1

4338-47-0Synthetic route

furan-2-ylmethanamine
617-89-0

furan-2-ylmethanamine

6-Chloropurine riboside
2004-06-0

6-Chloropurine riboside

kinetin riboside
4338-47-0

kinetin riboside

Conditions
ConditionsYield
With triethylamine In ethanol at 60℃; for 18h; Temperature;93%
With triethylamine In ethanol at 60℃; for 18h; Substitution;
kinetin
525-79-1

kinetin

α-D-ribofuranose-1-O-phosphate barium salt

α-D-ribofuranose-1-O-phosphate barium salt

kinetin riboside
4338-47-0

kinetin riboside

Conditions
ConditionsYield
With recombinant E. coli purine nucleoside phosphorylase; tris hydrochloride In water pH=8;93%
(2R,3R,4S,5R)-2-{6-[(Benzotriazol-1-yl-furan-2-yl-methyl)-amino]-purin-9-yl}-5-hydroxymethyl-tetrahydro-furan-3,4-diol

(2R,3R,4S,5R)-2-{6-[(Benzotriazol-1-yl-furan-2-yl-methyl)-amino]-purin-9-yl}-5-hydroxymethyl-tetrahydro-furan-3,4-diol

kinetin riboside
4338-47-0

kinetin riboside

Conditions
ConditionsYield
With sodium tetrahydroborate In tetrahydrofuran for 8h; reductive cleavage; Heating;85%
furan-2-ylmethanamine
617-89-0

furan-2-ylmethanamine

6-methylmercaptopurine riboside
342-69-8

6-methylmercaptopurine riboside

kinetin riboside
4338-47-0

kinetin riboside

Conditions
ConditionsYield
With water
furan-2-ylmethanamine
617-89-0

furan-2-ylmethanamine

(2R,3R,4R,5R)-2-((benzoyloxy)methyl)-5-(6-chloro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl dibenzoate
3510-73-4

(2R,3R,4R,5R)-2-((benzoyloxy)methyl)-5-(6-chloro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl dibenzoate

kinetin riboside
4338-47-0

kinetin riboside

Conditions
ConditionsYield
With 2-methoxy-ethanol Erwaermen des Reaktionsprodukts mit methanol.Natriummethylat;
furfural
98-01-1

furfural

adenosine
58-61-7

adenosine

kinetin riboside
4338-47-0

kinetin riboside

Conditions
ConditionsYield
With hydrogenchloride; sodium cyanoborohydride In methanol; water at 37℃; for 28h; pH 4.4;
furfural
98-01-1

furfural

ArgoGel-Rink resin bound NH2COCH2NH2

ArgoGel-Rink resin bound NH2COCH2NH2

kinetin riboside
4338-47-0

kinetin riboside

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 82 percent / AcOH / ethanol / 6 h / Heating
2: 85 percent / NaBH4 / tetrahydrofuran / 8 h / Heating
View Scheme
adenosine
58-61-7

adenosine

kinetin riboside
4338-47-0

kinetin riboside

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 82 percent / AcOH / ethanol / 6 h / Heating
2: 85 percent / NaBH4 / tetrahydrofuran / 8 h / Heating
View Scheme
Multi-step reaction with 3 steps
1: pyridine / 20 - 60 °C
2: triphenylphosphine; diethylazodicarboxylate / tetrahydrofuran / 20 °C
3: methanol; ammonia / 48 h / 20 °C
View Scheme
Multi-step reaction with 3 steps
1.1: pyridine / 20 - 60 °C
1.2: 20 °C
2.1: triphenylphosphine; diethylazodicarboxylate / tetrahydrofuran / 20 °C
3.1: methanol; ammonia / 48 h / 20 °C
View Scheme
2,3,5-tri-O-acetyl-α-D-ribofuranosyl chloride
105499-44-3

2,3,5-tri-O-acetyl-α-D-ribofuranosyl chloride

kinetin riboside
4338-47-0

kinetin riboside

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: anschliessende Entacetylierung
2: H2O
View Scheme
2,3,5-(tri-O-benzoyl)-D-ribofuranosyl chloride
5991-01-5

2,3,5-(tri-O-benzoyl)-D-ribofuranosyl chloride

kinetin riboside
4338-47-0

kinetin riboside

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: xylene
2: 2-methoxy-ethanol / Erwaermen des Reaktionsprodukts mit methanol.Natriummethylat
View Scheme
kinetin
525-79-1

kinetin

kinetin riboside
4338-47-0

kinetin riboside

Conditions
ConditionsYield
With purine nucleoside phosphorylase; potassium phosphate buffer at 50℃; pH=7.0;
6-N-2',3',5'-tri-O-tetraacetyladenosine
7387-58-8, 80007-24-5

6-N-2',3',5'-tri-O-tetraacetyladenosine

kinetin riboside
4338-47-0

kinetin riboside

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: triphenylphosphine; diethylazodicarboxylate / tetrahydrofuran / 20 °C
2: methanol; ammonia / 48 h / 20 °C
View Scheme
(2-furyl)methyl alcohol
98-00-0

(2-furyl)methyl alcohol

kinetin riboside
4338-47-0

kinetin riboside

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: triphenylphosphine; diethylazodicarboxylate / tetrahydrofuran / 20 °C
2: methanol; ammonia / 48 h / 20 °C
View Scheme
C23H25N5O9
1338578-79-2

C23H25N5O9

kinetin riboside
4338-47-0

kinetin riboside

Conditions
ConditionsYield
With methanol; ammonia at 20℃; for 48h;251 mg
With ammonia In methanol at 20℃; for 48h;
With propylamine In methanol at 20℃;
furfural
98-01-1

furfural

kinetin riboside
4338-47-0

kinetin riboside

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: hydroxylamine hydrochloride; sodium acetate / ethanol / 6 h / 20 °C
2: hydrogenchloride; hydrogen / palladium 10% on activated carbon / ethanol; water / 760.05 Torr
3: triethylamine / propan-1-ol / 8 h / 70 °C
View Scheme
furan-2-ylmethanamine hydrochloride
4753-68-8

furan-2-ylmethanamine hydrochloride

6-Chloropurine riboside
2004-06-0

6-Chloropurine riboside

kinetin riboside
4338-47-0

kinetin riboside

Conditions
ConditionsYield
With triethylamine In propan-1-ol at 70℃; for 8h;
With triethylamine In propan-1-ol at 70℃; for 8h; stereospecific reaction;220 mg
With triethylamine In propan-1-ol at 70℃; for 8h;220 mg
2-furaldehyde oxime
1121-47-7

2-furaldehyde oxime

kinetin riboside
4338-47-0

kinetin riboside

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: hydrogenchloride; hydrogen / palladium 10% on activated carbon / ethanol; water / 760.05 Torr
2: triethylamine / propan-1-ol / 8 h / 70 °C
View Scheme
2-sulfoxymethylfuran

2-sulfoxymethylfuran

adenosine
58-61-7

adenosine

kinetin riboside
4338-47-0

kinetin riboside

Conditions
ConditionsYield
In aq. phosphate buffer at 37℃; for 0.25h; pH=8;
6-N-2',3',5'-tri-O-tetraacetyladenosine
7387-58-8, 80007-24-5

6-N-2',3',5'-tri-O-tetraacetyladenosine

(2-furyl)methyl alcohol
98-00-0

(2-furyl)methyl alcohol

kinetin riboside
4338-47-0

kinetin riboside

Conditions
ConditionsYield
Mitsunobu Displacement;
uridine
58-96-8

uridine

kinetin riboside
4338-47-0

kinetin riboside

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: magnesium(II) chloride hexahydrate; recombinant E. coli uridine phosphorylase / aq. phosphate buffer / 23 °C / pH 7.0
1.2: 4 °C / pH 8.0
2.1: tris hydrochloride; recombinant E. coli purine nucleoside phosphorylase / water / pH 8
View Scheme
α-D-ribofuranosyl-1-phosphate

α-D-ribofuranosyl-1-phosphate

kinetin
525-79-1

kinetin

kinetin riboside
4338-47-0

kinetin riboside

Conditions
ConditionsYield
With magnesium(II) chloride hexahydrate; recombinant E. coli purine nucleoside phosphorylase In water at 50℃; for 144h; pH=7.0;
cis-dichlorobis(dimethylsulfoxide)platinum(II)
75992-73-3, 25794-47-2, 30729-25-0, 15274-33-6, 22840-91-1, 14568-13-9

cis-dichlorobis(dimethylsulfoxide)platinum(II)

kinetin riboside
4338-47-0

kinetin riboside

cis-[PtCl2(dimethyl sulfoxide)(kinetin riboside)]

cis-[PtCl2(dimethyl sulfoxide)(kinetin riboside)]

Conditions
ConditionsYield
In ethanol at 20 - 45℃; for 29h;60%
phenyl(isopropoxy-L-alaninyl) phosphorochloridate
261909-49-3

phenyl(isopropoxy-L-alaninyl) phosphorochloridate

kinetin riboside
4338-47-0

kinetin riboside

phenyl (isopropoxy-L-alaninyl) kinetin riboside phosphoramidate

phenyl (isopropoxy-L-alaninyl) kinetin riboside phosphoramidate

Conditions
ConditionsYield
Stage #1: kinetin riboside With 1-methyl-1H-imidazole In tetrahydrofuran at 20℃; for 0.416667h; Inert atmosphere;
Stage #2: phenyl(isopropoxy-L-alaninyl) phosphorochloridate In tetrahydrofuran at 20℃; for 18h; Inert atmosphere;
42%
phenyl (tert-butyloxy-L-alaninyl)phosphorochloridate
220592-63-2

phenyl (tert-butyloxy-L-alaninyl)phosphorochloridate

kinetin riboside
4338-47-0

kinetin riboside

phenyl (tert-butyloxy-L-alaninyl) kinetin riboside phosphoramidate

phenyl (tert-butyloxy-L-alaninyl) kinetin riboside phosphoramidate

Conditions
ConditionsYield
Stage #1: kinetin riboside With 1-methyl-1H-imidazole In tetrahydrofuran at 20℃; for 0.416667h; Inert atmosphere;
Stage #2: phenyl (tert-butyloxy-L-alaninyl)phosphorochloridate In tetrahydrofuran at 20℃; for 18h; Inert atmosphere;
14%
kinetin riboside
4338-47-0

kinetin riboside

phenyl(benzyloxy-L-alaninyl)phosphorochloridate
183370-70-9

phenyl(benzyloxy-L-alaninyl)phosphorochloridate

phenyl (benzyloxy-L-alaninyl) kinetin riboside phosphoramidate

phenyl (benzyloxy-L-alaninyl) kinetin riboside phosphoramidate

Conditions
ConditionsYield
Stage #1: kinetin riboside With 1-methyl-1H-imidazole In tetrahydrofuran at 20℃; for 0.416667h; Inert atmosphere;
Stage #2: phenyl(benzyloxy-L-alaninyl)phosphorochloridate In tetrahydrofuran at 20℃; for 18h; Inert atmosphere;
13%
kinetin riboside
4338-47-0

kinetin riboside

phenyl methoxyalaninyl phosphorochloridate
142629-80-9

phenyl methoxyalaninyl phosphorochloridate

phenyl (methoxy-L-alaninyl) kinetin riboside phosphoramidate

phenyl (methoxy-L-alaninyl) kinetin riboside phosphoramidate

Conditions
ConditionsYield
Stage #1: kinetin riboside With tert-butylmagnesium chloride In tetrahydrofuran at 20℃; for 0.416667h; Inert atmosphere;
Stage #2: phenyl methoxyalaninyl phosphorochloridate In tetrahydrofuran at 20℃; for 18h; Inert atmosphere;
10%
kinetin riboside
4338-47-0

kinetin riboside

A

kinetin
525-79-1

kinetin

B

α-D-ribofuranosyl-1-phosphate
18646-11-2

α-D-ribofuranosyl-1-phosphate

Conditions
ConditionsYield
With Escherichia coli purine nucleoside phosphorylase at 25℃; pH=7.5; Kinetics; aq. phosphate buffer; Enzymatic reaction;
With potassium dihydrogenphosphate; Escherichia coli purine nucleoside phosphorylase at 37℃; pH=7.5; Equilibrium constant; aq. buffer; Enzymatic reaction;

4338-47-0Relevant articles and documents

Bioactivation of food genotoxicants 5-hydroxymethylfurfural and furfuryl alcohol by sulfotransferases from human, mouse and rat: a comparative study

Sachse, Benjamin,Meinl, Walter,Sommer, Yasmin,Glatt, Hansruedi,Seidel, Albrecht,Monien, Bernhard H.

, p. 137 - 148 (2016)

5-Hydroxymethylfurfural (HMF) and furfuryl alcohol (FFA) are moderately potent rodent carcinogens that are present in thermally processed foodstuffs. The carcinogenic effects were hypothesized to originate from sulfotransferase (SULT)-mediated bioactivation yielding DNA-reactive and mutagenic sulfate esters, a confirmed metabolic pathway of HMF and FFA in mice. It is known that orthologous SULT forms substantially differ in substrate specificity and tissue distribution. This could influence HMF- and FFA-induced carcinogenic effects. Here, we studied HMF and FFA sulfoconjugation by 30 individual SULT forms of humans, mice and rats. The catalytic efficiencies (kcat/KM) of HMF sulfoconjugation of human SULT1A1 (13.7?s?1?M?1), mouse Sult1a1 (15.8?s?1?M?1) and 1d1 (4.8?s?1?M?1) and rat Sult1a1 (5.3?s?1?M?1) were considerably higher than those of all other SULT forms investigated (≤0.73?s?1M?1). FFA sulfoconjugation was monitored using adenosine as a nucleophilic scavenger for the reactive 2-sulfoxymethylfuran (t1/2?=?20?s at 37?°C). The resulting adduct N6-((furan-2-yl)methyl)-adenosine (N6-MF-A) was quantified by isotope-dilution UPLC-MS/MS. The rates of N6-MF-A formation showed that hSULT1A1 and its orthologues in mice and rats were also the most important contributors to FFA sulfoconjugation in each of the species. Taken together, the catalytic capacity of hSULT1A1 is comparable to that of mSult1a1 in mice, the species in which carcinogenic effects of HMF and FFA were detected. This is of primary concern due to the expression of hSULT1A1 in many different tissues.

Anion exchange resins in phosphate form as versatile carriers for the reactions catalyzed by nucleoside phosphorylases

Artsemyeva, Julia N.,Buravskaya, Tatiana N.,Esipov, Roman S.,Konstantinova, Irina D.,Litvinko, Natalia M.,Mikhailopulo, Igor A.,Miroshnikov, Anatoly I.,Remeeva, Ekaterina A.

, p. 2607 - 2622 (2020/11/26)

In the present work, we suggested anion exchange resins in the phosphate form as a source of phosphate, one of the substrates of the phosphorolysis of uridine, thymidine, and 1-(β-D-arabinofuranosyl)uracil (Ara-U) catalyzed by recombinant E. coli uridine (UP) and thymidine (TP) phosphorylases. α-D-Pentofuranose-1-phosphates (PF-1Pis) obtained by phosphorolysis were used in the enzymatic synthesis of nucleosides. It was found that phosphorolysis of uridine, thymidine, and Ara-U in the presence of Dowex 1X8 (phosphate; Dowex-nPi) proceeded smoothly in the presence of magnesium cations in water at 20-50 °C for 54-96 h giving rise to quantitative formation of the corresponding pyrimidine bases and PF-1Pis. The resulting PF-1Pis can be used in three routes: (1) preparation of barium salts of PF-1Pis, (2) synthesis of nucleosides by reacting the crude PF-1Pi with an heterocyclic base, and (3) synthesis of nucleosides by reacting the ionically bound PF-1Pi to the resin with an heterocyclic base. These three approaches were tested in the synthesis of nelarabine, kinetin riboside, and cladribine with good to excellent yields (52-93%).

Multinuclear magnetic resonance characterization and antiproliferative studies of novel dichlorido platinum(II) complexes containing kinetin riboside and 1-β-D-ribofuranosyl-4-(2-pyridyl)-1H-1,2,3-triazole

Jakubowski, Mateusz,?akomska, Iwona,Sitkowski, Jerzy,Pokrywczyńska, Marta,D?browski, Pawe?,Framski, Grzegorz,Ostrowski, Tomasz

, (2020/02/15)

The chemical reaction between cis-[PtCl2(dmso)2] and kinetin riboside (KR) or 1-β-D-ribofuranosyl-4-(2-pyridyl)-1H-1,2,3-triazole (PTR) has resulted in two novel platinum(II) complexes being obtained with different compositions of the coordination sphere: cis-[PtCl2(PTR)] (1) and cis-[PtCl2(dmso)(KR)] (2). Based on multinuclear NMR results (1H, 13C, 15N, 195Pt), we have demonstrated that the N-donor ligands PTR and KR are able to coordinate to the Pt(II) ion as bidentate via two nitrogen atoms (N(3) and N(7)) or monodentate via only one nitrogen atom (N(7)), respectively. On the other hand, biological studies showed that the novel platinum(II) complexes exhibit different in vitro cytotoxicity towards A549 (lung carcinoma epithelial cells), T24 (urinary bladder cancer cells) and CRL1872 (malignant melanoma cells). The complex cis-[PtCl2(dmso)(KR)] (2) shows in vitro cytotoxicity against T24 and CRL1872 cell lines (the IC50 parameters amount to 52.2 μM and 21.4 μM, respectively), whereas cis-[PtCl2(PTR)] (1) is not able to inhibit a proliferation of these cells in the range of tested concentrations.

New tools in nucleoside toolbox of tick-borne encephalitis virus reproduction inhibitors

Orlov, Alexey A.,Drenichev, Mikhail S.,Oslovsky, Vladimir E.,Kurochkin, Nikolay N.,Solyev, Pavel N.,Kozlovskaya, Liubov I.,Palyulin, Vladimir A.,Karganova, Galina G.,Mikhailov, Sergey N.,Osolodkin, Dmitry I.

supporting information, p. 1267 - 1273 (2017/06/19)

Design and development of nucleoside analogs is an established strategy in the antiviral drug discovery field. Nevertheless, for many viruses the coverage of structure-activity relationships (SAR) in the nucleoside chemical space is not sufficient. Here we present the nucleoside SAR exploration for tick-borne encephalitis virus (TBEV), a member of Flavivirus genus. Promising antiviral activity may be achieved by introduction of large hydrophobic substituents in the position 6 of adenosine or bulky silyl groups to the position 5′. Introduction of methyls to the ribose moiety does not lead to inhibition of TBEV reproduction. Possible mechanisms of action of these nucleosides include the inhibition of viral entry or interaction with TBEV non-structural protein 5 methyltransferase or RNA-dependent RNA polymerase domains.

Kinetin Riboside and Its ProTides Activate the Parkinson’s Disease Associated PTEN-Induced Putative Kinase 1 (PINK1) Independent of Mitochondrial Depolarization

Osgerby, Laura,Lai, Yu-Chiang,Thornton, Peter J.,Amalfitano, Joseph,Le Duff, Cécile S.,Jabeen, Iqra,Kadri, Hachemi,Miccoli, Ageo,Tucker, James H. R.,Muqit, Miratul M. K.,Mehellou, Youcef

, p. 3518 - 3524 (2017/05/05)

Since loss of function mutations of PINK1 lead to early onset Parkinson’s disease, there has been growing interest in the discovery of small molecules that amplify the kinase activity of PINK1. We herein report the design, synthesis, serum stability, and hydrolysis of four kinetin riboside ProTides. These ProTides, along with kinetin riboside, activated PINK1 in cells independent of mitochondrial depolarization. This highlights the potential of modified nucleosides and their phosphate prodrugs as treatments for neurodegenerative diseases.

APPLICATIONS OF N6-SUBSTITUTED ADENOSINE DERIVATIVE AND N6-SUBSTITUTED ADENINE DERIVATIVE TO CALMING, HYPNOSES, CONVULSION RESISTANCE, EPILEPTIC RESISTANCE, PARKINSON DISEASE RESISTANCE, AND DEMENTIA PREVENTION AND TREATMENT

-

Paragraph 010, (2018/10/27)

PROBLEM TO BE SOLVED: To prepare analgesics, hypnotic agents, anticonvulsant agents, antiepileptics, antiparkinson drugs, dementia prophylactics, and health care food. SOLUTION: The present invention relates to an N6-substituted adenosine derivative and an N6-substituted adenine derivative selected from the group consisting of specific compounds. The present invention also relates to a pharmaceutical composition at least comprising a therapeutically effective amount of the compounds and a pharmaceutically acceptable carrier. The invention further relates to the compounds used in preparation of analgesics, hypnotic agents, anticonvulsant agents, antiepileptics, antiparkinson drugs, dementia prophylactics, and health care food. COPYRIGHT: (C)2016,JPO&INPIT

N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF

-

Paragraph 0136; 0139, (2013/03/26)

The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.

N6-SUBSTITUTED ADENOSINE DERIVATIVES, N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF

-

Page/Page column 46, (2012/11/06)

The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.

N6-acetyl-2,3,5-tri-O-acetyladenosine; A convenient, missed out substrate for regioselective N6-alkylations

Tararov, Vitali I.,Kolyachkina, Svetlana V.,Alexeev, Cyril S.,Mikhailov, Sergey N.

, p. 2483 - 2489 (2011/09/20)

A simple and efficient route to N6-acetyl-2,3,5-tri-O- acetyladenosine (1) was developed based on selective N-deacetylation of pentaacetylated adenosine 2 with methanol at room temperature in the presence of imidazole. Preparative synthesis of 1 was elaborated utilizing a crude mixture of 2 and 1 which is produced by reaction of adenosine with acetic anhydride in pyridine at elevated temperatures. The total yield of 1 was 80-85% starting with adenosine. It was shown that 1 is a convenient substrate for selective N 6-alkylations. The study revealed the same regioselectivity in base-promoted reactions of 1 with activated alkyl halides and Mitsunobu reactions of 1 with alcohols. A series of N6-alkyladenosines 5a-f were prepared. Cytokinins 6b,d,e were prepared by enzymatic transformation of parent nucleoside derivatives 5b,d,e using a combination of nucleoside phosphorylase and alkaline phosphatase. Georg Thieme Verlag Stuttgart, New York.

N6-Substituted adenosines. Cytokinin and antitumor activities

Kolyachkina, Svetlana V.,Tararov, Vitali I.,Alexeev, Cyril S.,Krivosheev, Dmitry M.,Romanov, Georgy A.,Stepanova, Evgenia V.,Solomko, Eliso S.,Inshakov, Andrey N.,Mikhailov, Sergey N.

scheme or table, p. 1361 - 1378 (2012/04/04)

A series of N6-adenosine derivatives were synthesized by alkylation of N6-acetyl-2',3',5'-tri-O-acetyladenosine (1) with alkyl halides and alcohols. It was shown that propargyl derivative 2a is a good substrate for copper(I) catalyzed Huisgen [3+2] cycloaddition with azides. This click-reaction can be used for preparation of the libraries of 1,2,3-triazolyl modified adenosines. Biological activities of N6-adenosines were studied in two plant and six human cancer cell assays. The remarkable parallel between cytokinin and cytotoxic activities was found. The most cytokinin active compounds 3c-3e at the same time appeared to be the most potent cytotoxic agents.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 4338-47-0